AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 62 min read$SXTP

60 Degrees Pharmaceuticals Sets January 2027 Babesiosis Data Readout and Plans FDA Pre-sNDA Meeting

60 Degrees Pharmaceuticals (SXTP) plans to report data from its tafenoquine babesiosis study in January 2027, ending enrollment at 30 patients. The company will seek FDA feedback on a potential sNDA pathway, possibly using molecular clearance as a surrogate endpoint. Results may impact tafenoquine's development for babesiosis.

Original reporting
finance.yahoo.com
Published Oct 6, 2026, 2:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 3:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
60 Degrees Pharmaceuticals Sets January 2027 Babesiosis Data Readout and Plans FDA Pre-sNDA Meeting — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$SXTPNeutralLow
01

Why it matters

The announced January 2027 readout and pre‑sNDA meeting create a clear, time‑bound catalyst that could materially affect the stock price, depending on trial outcomes and FDA response.

02

Market read

The article provides the first public disclosure of a concrete data readout date and regulatory meeting plan, offering a new trading catalyst for SXTP.

03

What to watch

The expanded‑access case reports and potential NAT‑based surrogate endpoint could mitigate a negative trial outcome.

Relevance 8/10Novelty 8/10Timing: January 2027 data readout

Background

60 Degrees Pharmaceuticals (NASDAQ:SXTP) is developing tafenoquine for severe babesiosis, a rare tick‑borne disease. The company has reduced its trial enrollment to 30 patients and will seek FDA feedback on an accelerated‑approval pathway.

Company-level read

Ticker impact

$SXTPNeutralHigh confidence
Context

60 Degrees Pharmaceuticals announced a January 2027 readout of its severe babesiosis trial and plans a pre-sNDA meeting, providing a new regulatory and data catalyst.

Expected impact

potential upside if trial shows efficacy; downside pressure if results are inconclusive or safety concerns arise.

Evidence & confidence

Investors will price in the binary outcome of the trial; the market currently lacks concrete efficacy data.

Market effects

Sector

Positive babesia data could boost the infectious‑disease biotech sector and raise interest in accelerated‑approval pathways.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minimal global impact unless trial results trigger wider regulatory discussion.

Counterpoint

What could challenge this read

If the trial fails, the stock may experience a sharp sell‑off as investors reassess the drug's viability.

Key entities

  • company
    60 Degrees Pharmaceuticals

    Biotech firm developing tafenoquine for babesiosis.

  • regulator
    FDA

    U.S. agency that will review the pre‑sNDA meeting request.

Read at source← All news

Story60 Degrees to unblind severe babesiosis trial and seek FDA pre‑sNDA meeting in January 2027

Also covered by

1 outlet

Related articles

OCT 27
$SXTPMedAI 8/10

60 Degrees Reports Negative Babesia PCR Results In Completed Expanded Access Patients; Stock Down

60 Degrees Pharmaceuticals (SXTP) reported negative PCR results in 5 patients from its expanded access study of tafenoquine for babesiosis, with 4 also testing negative on a sensitive NAT test. All patients showed clinical improvement. The stock is down 29% to $0.60. The company expects to unblind a separate study in January 2027. Tafenoquine is not FDA-approved for babesiosis.

rttnews.com2 min
OCT 27
$SXTPMedAI 8/10

60 Degrees Pharmaceuticals (SXTP) Reports PCR-Negative Outcomes in 5 Babesiosis Patients

60 Degrees Pharmaceuticals (SXTP) reported that all 5 completed patients in its expanded access study showed clinical improvement and tested negative for Babesia via PCR, with 4/5 also NAT-negative post-treatment. The company may seek accelerated FDA approval using NAT nonreactivity as a surrogate. Two additional patients are currently being treated, with a total enrollment of 7. The study remains open pending potential FDA discussions.

tradingview.com1 min
OCT 27
$SXTPMedAI 8/10

All five patients reported improvement; a sensitive post-treatment test found no parasite in four.

60 Degrees Pharmaceuticals reported that all five patients in its expanded access study for relapsing babesiosis showed significant improvement and tested negative for the parasite. Four of five patients also tested negative on highly sensitive NAT testing. The study evaluates tafenoquine-containing regimens and remains open with seven patients enrolled. The company plans to discuss potential FDA approval pathways.

stocktitan.net2 min
OCT 27
$SXTPMedAI 8/10

60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients

60 DEGREES PHARMACEUTICALS, INC. (SXTP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients ● All five completed patients (100%) reported much or very much improved clinical outcomes and tested negative for Babesia on

SEC EDGAR 8-K2 min